```markdown
# ANTIMUOR EFFECT OF CDK INHIBITOR, FLAVOPIRIDOL

## a
ANTITUMOR EFFECT OF CDK INHIBITOR, FLAVOPIRIDOL

| 0 6 12 18 24 48 (hr) | 0 6 12 18 24 48 (hr) | P ADR | P ADR |
|------------------------|------------------------|-------|-------|
| Caspase-9                | Flavopiridol (nM)        | 0 400 400 | 0 320 320 |
| Caspase-3                | Cytochrome c (cytosol) |         |         |
| Caspase-8                | Actin                   |         |         |
| 47kDa                    | MNNG                     |         |         |
| 32kDa                    | WE-68                     |         |         |
| 55/50kDa                |                         |         |         |
| 44/40kDa                |                         |         |         |
| 23kDa                    |                         |         |         |
| Actin                     |                         |         |         |

## b
ANTITUMOR EFFECT OF CDK INHIBITOR, FLAVOPIRID

| MNNG/ADR | WE-68/ADR |
|-----------|-----------|
| P53        |           |
| Bax        |           |
| Bcl-xL    |           |
| Bcl-2     |           |
| Actin     |           |

| 0 100 400 600M | 0 80 160 320M |
|----------------|---------------|
| Flavopiridol (200nM) |               |
| Z-VAD-FMK (75uM) |               |
| Z-IETD-FMK (75uM) |               |
| Z-DEVD-FMK (50uM) |               |

## c
ANTITUMOR EFFECT OF CDK INHIBITOR, FLAVOPIRID 

| Flavopiridol (200nM) | Z-VAD-FMK (75uM) | Z-IETD-FMK (75uM) | Z-DEVD-FMK (50uM) |
|-----------------------|-------------------|---------------------|---------------------|
| Cleaved PARP          | 85kDa              | 32kDa               |                     |
| Caspase-3              |                     |                     |                     |
| Actin                   |                     |                     |                     |

## Figure 3
Induction of caspase-dependent apoptosis by flavopiridol in the ADR clones of OS or EFTs, MNNG/ADR or WE-68/ADR cells were treated with 200 nM (left panel) or 400 nM (right panel) of flavopiridol for 24 hr. The cells were treated with 200 nM of MNNG or WE-68 for 1 hr and then cultured for 24 hr. The cells were treated with various concentrations of flavopiridol for 24 hr. and then analyzed by Western blot analysis as described in Materials and Methods. EFTs were treated with various concentrations of flavopiridol for 24 hr. and then analyzed using anti-p53, Bax, Bcl-xL, Bcl-2, and actin antibodies.

## Figure 4
The apoptotic effect of flavopiridol was mainly mediated by mitochondrial pathway in the ADR clones of OS and EFTs. We next investigated whether the activation of caspase-9 and caspase-3 could lead to the release of cytochrome c. Treatments of parental and ADR inhibitor (Z-VAD-FMK), caspase-8 inhibitor (Z-IETD-FMK), or caspase-3 inhibitor (Z-DEVD-FMK) or caspase-9 inhibitor (Z-LEHD-FMK) were carried out using 400 nM flavopiridol in the ADR clones of OS or EFTs. The cells were treated with 200 nM of MNNG or WE-68 for 24 hr. The viability of cells was measured by MTT assay. The caspase-3/7 activity was measured by Caspase-Glo™ assay. The caspase-8 activity was measured by Caspase-Glo™ assay. The caspase-9 activity was measured by Caspase-Glo™ assay. The caspase-3/7 activity was measured by Caspase-Glo® assay. The caspase-8 activity was measured by Caspase-Glo® assay. The caspase-9 activity was measured by Caspase-Glo® assay. The caspase-3/7 activity was measured by Caspase-Glo assay. The caspase-8 activity was measured by Caspase-Glo assay. The caspase-9 activity was measured by Caspase-Glo assay. The caspase-3/7 activity was measured by Caspase-Glo 3/7 assay. The caspase-8 activity was measured by Caspase-Glo 8 assay. The caspase-9 activity was measured by Caspase-Glo 9 assay. The caspase-3/7 activity was measured by Caspase-Glo. The caspase-8 activity was measured by Caspase-Glo. The caspase-9 activity was measured by Caspase-Glo. The caspase-3/7 activity was measured by Caspase-Glo. 

## Figure 5
Flavopiridol inhibited MNNG-induced growth of the drug-resistant OS and EFTs tumors in mice. Since flavopiridol displayed anti-proliferative effects in vitro, we set out to investigate the antiproliferative activity of flavopiridol in vivo.

## Figure 6
Flavopiridol inhibited MNNG-induced growth of the drug-resistant OS and EETs tumors in mice. Since flavopiridol displayed anti-proliferative effects in vivo, we set out to investigate the antiproliferative activity of flavopiridol.

## Figure 7
Flavopiridol inhibited MNNG-induced growth of the drug-resistant OS and EETS tumors in mice. Since flavopiridol displayed anti-proliferative effects in vivo and in vitro, we set out to investigate the antiproliferative activity of flavopirido

## Figure 8
Flavopiridol inhibited MNNG-induced growth of the drug-resistant OS and EFS tumors in mice. Since flavopiridol displayed anti-proliferative effects in vivo.

## Figure 9
Flavopiridol inhibited MNNG-induced growth of the drug-resistant OS and EES tumors in mice. Since flavopiridol displayed anti-proliferative effects in vivo.
```